

# WHAT IS CR<sup>2</sup>O?

- We are an academic research organization that focusses on managing and operating clinical trials for vaccine-, drug-, and diagnostics development by industry and public organizations.
- With headquarters in Amsterdam and Rotterdam, The Netherlands, CR<sup>2</sup>O has built extensive experience managing and implementing phase I-IV clinical trials in over 30 countries and accumulated expertise through >400 studies over the last decade.
- World-class academic expertise in viral and other infectious diseases, with state of the art clinical infrastructure and high quality research facilities.
- Our unique combination of scientific expertise, operational efficiency and access to subjects make us an attractive partner for pharma, biotech and public organizations.



**PROJECT MANAGEMENT**



**CLINICAL MONITORING**



**QUALITY MANAGEMENT**



**BIostatISTICS & DATA MANAGEMENT**



**PHARMACOVIGILANCE**



**MEDICAL WRITING**



**INSOURCING**



**Hadil Es-Sbai**  
MSc.  
Chief Executive Officer



**Prof. A.D.M.E Osterhaus**  
PhD, DVM  
Chief Scientific Officer



## OUR STRENGTHS

- Full service CRO
- European coverage
- Expert-CRO: investigator initiated clinical trials
- Expert-CRO: in the field of subsidized studies (i.e. Horizon2020, IMI)
- Established collaborations with leading infectious disease clinics and research centers all over the world
- One dedicated contact throughout the trial life cycle

## CONTACT US

### AMSTERDAM OFFICE



Joop Geesinkweg 701  
1114 AB  
Amsterdam  
Duivendrecht  
The Netherlands

### ROTTERDAM OFFICE



Marconistraat 16  
3029 AK  
Rotterdam  
The Netherlands

[www.cr2o.nl](http://www.cr2o.nl) | [info@cr2o.nl](mailto:info@cr2o.nl)



## RESPIRATORY SYNCYTIAL VIRUS

- Respiratory syncytial virus (RSV) infection and bronchiolitis represents a worldwide health problem, with a substantial disease burden in children under 5.
- RSV hospital outbreaks (nosocomial transmission) can have devastating outcomes among immunocompromised patients.
- 66.000–199.000 estimated deaths worldwide per year.
- Evidence-based guidelines offer no obviously effective therapeutic interventions so far.
- Currently, huge investment in RSV therapeutics by emerging RSV pharmaceuticals and vaccines.

- STRIDE is a highly interactive and collaborating entity that covers **ALL R&D** activities that will bring **NOVEL** ideas for HRSV intervention strategies in an **INTEGRATED** way from basic scientific discoveries, via preclinical and clinical studies to clinical use.
- Offering more value to clients by combining expertise into integrated project teams.



### LEAD PARTNER



### PARTNERS



Biointelect.



BASIC R&D

TiHo-RIZ

PRE-CLINICAL R&D

TiHo-RIZ

Viroclinics Biosciences

CLINICAL LABORATORY R&D

Viroclinics Biosciences

CLINICAL R&D

CR<sup>2</sup>O

Julius Clinical

Biointelect

COMMERCIALISATION

Biointelect